The VEGF-R inhibitor PTK787/ZK222584 (PTK/ZK) also inhibits aromatase: preclinical studies of PTK/ZK in combination with endocrine therapy

被引：0
|
作者：
Banerjee, S. N.
Thornhill, A.
Evans, D. B.
Littlewood-Evans, A. J.
Dowsett, M.
Martin, L-A
机构：
[1] Inst Canc Res, London SW3 6JB, England
[2] Novartis Inst Biomed Res, Basel, Switzerland
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [31] Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: An animal study
    Schoenberger, J
    Grimm, D
    Kossmehl, P
    Infanger, M
    Kurth, E
    Eilles, C
    ENDOCRINOLOGY, 2004, 145 (03) : 1031 - 1038
  • [32] A phase I/II trial of single-agent PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM)
    Yung, W. K. Alfred
    Friedman, H.
    Reardon, D.
    Provenzale, J.
    Jackson, E.
    Serajuddin, H.
    Laurent, D.
    Chen, B.
    Conrad, C.
    ANNALS OF ONCOLOGY, 2004, 15 : 207 - 207
  • [33] Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a nove, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer
    Vanhoefer, U.
    Trarbach, T.
    Schleucher, N.
    Junker, U.
    Tewes, M.
    Masson, E.
    Lebwohl, D.
    Seeber, S.
    Laurent, D.
    ANNALS OF ONCOLOGY, 2004, 15 : 94 - 95
  • [34] EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
    Brandes, Alba A.
    Stupp, Roger
    Hau, Peter
    Lacombe, Denis
    Gorlia, Thierry
    Tosoni, Alicia
    Mirimanoff, Rene O.
    Kros, Johan M.
    van den Bent, Martin J.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (02) : 348 - 354
  • [35] Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis
    Schomber, Tibor
    Zumsteg, Adrian
    Strittmatter, Karin
    Crnic, Ivana
    Antoniadis, Helena
    Littlewood-Evans, Amanda
    Wood, Jeanette
    Christofori, Gerhard
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (01) : 55 - 63
  • [36] Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma
    Brander, Danielle M.
    Beaven, Anne W.
    Gockerman, Jon P.
    Diehl, Louis F.
    Gasparetto, Cristina
    Shea, Thomas C.
    deCastro, Carlos
    Moore, Joseph O.
    Rizzieri, David A.
    BLOOD, 2012, 120 (21)
  • [37] PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization
    Goldbrunner, RH
    Bendszus, M
    Wood, J
    Kiderlen, M
    Sasaki, M
    Tonn, JC
    NEUROSURGERY, 2004, 55 (02) : 426 - 432
  • [38] Intra-hippocampal administration of the VEGF receptor blocker PTK787/ZK222584 impairs long-term memory
    Pati, Shibani
    Orsi, Sara A.
    Moore, Anthony N.
    Dash, Pramod K.
    BRAIN RESEARCH, 2009, 1256 : 85 - 91
  • [39] Synergistic inhibitory effects of PTK787/ZK222584 and interferon-alfa on hepatocellular carcinoma with metastatic potential
    Liu, Yuqing
    Poon, Ronnie Tung-Ping
    Li, Lei
    Qian, Xuemin
    Chen, Yongjun
    Xu, Yang
    Sun, Huichuan
    Tang, Zhaoyou
    Fan, Sheungtat
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A94 - A94
  • [40] Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer (CRC).
    Trarbach, T
    Schleucher, N
    Tewes, M
    Seeber, S
    Junker, U
    Laurent, D
    Vanhoefer, U
    Masson, E
    Lebwohl, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 272S - 272S
12345